Allelica has created a secure and trusted platform for Polygenic Risk Score analysis and reporting. We equip health systems and clinical laboratories with cutting-edge tools to reduce the impact of common disease through genomic medicine.

Allelica has created a secure and trusted platform for Polygenic Risk Score analysis and reporting.
We equip health systems and clinical laboratories with cutting-edge tools to reduce the impact of common disease through genomic medicine.

Data-driven
disease prevention

Allelica’s software empowers health systems to reduce the burden of chronic disease through revolutionary preventive healthcare tools powered by the integration of patients’ clinical and genomic data.

Precision genomic
risk prediction

Allelica’s end-to-end Polygenic Risk Score pipeline provides clinical laboratories with a secure infrastructure for PRS analysis through to clinical reporting and can determine a patients’ absolute risk of common diseases through a simple file upload of their genotyped data.

Enabling cutting-edge research

Allelica’s PRS modules for new score discovery and validation perform the work of a team of bioinformaticians, enabling researchers to generate the best performing PRS using multiple gold standard algorithms in parallel and achieve publication ready results without months of bioinformatics efforts.

MERCK-LOGO

“With this agreement, Merck confirms its strong commitment in advancing Science and Technology in the therapeutic area of cardiovascular disorders.”

Antonio Messina, Merck General Manager

Read more →
MGZ

“MGZ Munich has stood for comprehensive human genetic diagnostics for over 20 years. Integrating the Polygenic Risk Score into our services enables us to provide physicians with a much more precise understanding of their patients’ absolute risk of complex diseases, serving as a critical tool in the development of effective primary prevention strategies.”

Andreas Laner
Head of Genomics Program NGS

Medipredict

“In our mission to keep our clients healthy, we provide personalized prevention plans based on integrated medical and omics data - Allelica's technology helps us to do that through data-driven risk prediction.”

Ernő Duda
Chairman of the Board, Medipredict Chairman of the Board,
Medipredict

Bioiatriki

“We’re delighted to partner with Allelica to translate the latest breakthroughs in genomic research into real advances in clinical care.”

Mina Hiona
Director,
Center for Preventive Medicine & Longevity
Director,
Center for Preventive Medicine & Longevity

Latest news

POLYGENIC RISK SCORE WEBINAR CO-HOSTED WITH CONGENICA

Allelica is joining forces with world leaders in genomic medicine at Congenica to provide an educational webinar focused on Polygenic Risk Score in clinical application. The speakers will cover the opportunities and challenges to widespread implementation for PRS in the UK and beyond.

ALLELICA CSO SPEAKS 2021 GENOMIC SUMMIT

Alongside international scientists, Allelica CSO, George Busby, presented on PRS at the largest genomics conference in Latin America. George discussed how PRS is applied in non-European populations and how PRS modulates penetrance of single gene mutations.

Research on the cost-effectiveness of PRS published in medRxiv

Together with researchers at University of Sydney and Illumina, Inc., Allelica researchers and health economist, Deo Mujwara, completed a study on the cost-saving power of PRS for health systems. The study focuses on application of PRS in heart disease risk assessments, specifically looking at the advantages of using PRS as a risk enhancing factor in the Pooled Cohort Equation.

Press conference with top cardiovascular groups and Merck

Alongside the three leading cardiovascular scientific societies in Italy, Allelica hosted a press conference focused on the commercialization of CardioriskSCORE, the CAD PRS developed by Allelica and published in Circulation. Participants discussed the impact this has on heart attack risk and its implications for more effective primary prevention strategies. The conference was attended by top cardiologists and pharmaceutical companies in Europe.

Pharmafile features interview with Allelica CEO

In the Spring 2021 edition, Pharmafile magazine interviewed Allelica CEO, Giordano Bottà, on the critical role Polygenic Risk Score plays in assessing patients’ risk of heart disease. The interview covers the process of PRS integration in existing cardiovascular disease risk assessment, and discusses how Allelica is helping to power rapid adoption of PRS for complex disease in the clinic.

Allelica CSO speaks at Oxford Personalised Medicine webinar

Allelica CSO, George Busby, presented on the increasingly important role of polygenic risk scores in precision medicine in the UK and beyond, highlighting the challenges and opportunities for PRS implementation at scale. The webinar was hosted by the Oxford Personalised Medicine Society, part of the Wellcome Trust Centre for Human Genetics & University of Oxford.

ALLELICA CEO FEATURED IN CLINICAL OMICS MAGAZINE

Allelica CEO and co-founder, Giordano Bottà, was interviewed as part of an editorial piece, Polygenic Risk Scores: Taking Hold in the Clinic, in the most recent version of Clinical Omics. He discusses the growing importance of PRS in healthcare and the opportunities it presents for chronic disease prevention.

Allelica CAD PRS Research in Circulation

Allelica researchers identified a critical interaction between PRS for coronary artery disease (CAD) and LDL cholesterol level.
Their discovery has major implications for clinical decision-making in primary prevention strategies. The research is now available in the American Heart Association Journal, Circulation.

Genomics Virtual Summit 2020

This event will showcase emerging and innovative applications advancing consumer & healthcare genomics to accelerate the adoption of precision medicine in healthcare systems. We will be discussing the life-saving potential of PRS for heart disease and its power to advance personalized lipid management.

The COVID-19 Host Genetics Initiative

Formed earlier this year, the COVID-19 Host Genetics Initiative is an open collaboration between scientists around the globe. It is focused on identifying genetic determinants of disease susceptibility and severity in order to understand why symptoms manifest in such drastically different ways. As participants in the initiative, we are developing scores to predict disease severity. We also built web and mobile digital tools to collect data from hospitalized patients.

Coronary Artery Disease Risk Calculator

Our newest product for healthcare providers calculates patients’ lifetime risk of developing coronary artery disease based on the integration of genetic and traditional risk factors using state of the art polygenic risk score. The interactive tool shows patients how manageable lifestyle changes and therapeutic interventions can actively lower lifetime risk of heart disease.

Genomic Medicine Virtual Conference

The Rady Children's Institute for Genomic Medicine Virtual Conference 2020, Integrating Genomic Medicine Across Systems, will dive deep into the latest innovations in genomic medicine. We will show our work alongside leaders in research and healthcare on how early polygenic risk score testing can reduce the lifetime risk of coronary artery disease.

ASHG Virtual Meeting

We are proud to have been selected as a “Reviewer's Choice” by the American Society of Human Genetics, being rated among the top 10% of abstracts. Our work will be presented at the ASHG Virtual Meeting 2020 where researchers will come together to present their latest discoveries and explore new tools & technologies to transform genomic medicine.

16th World Congress of Public Health

We are very excited to announce our participation in the 16th World Congress of Public Health, a conference which brings together some of the brightest minds and latest scientific developments from across the globe. Our presentation will focus on the role of polygenic risk scores in the prevention of common adult onset conditions.

Our Principles

Data Driven

Our products are developed and validated using world class datasets and state-of-the-art technology to ensure the highest level of quality.

Scientific Rigor

We are a group of international scientists and researchers committed to maintaining standards of academic excellence every step of the way.

Human-centricity

Everything we do works towards our common goal of providing tangible improvement in preventive healthcare to help humans live a longer, healthier life.

What we do

Perform genetic risk analysis

Allelica's Polygenic Risk Scores for common diseases have the highest predictive power on the market, allowing physicians to more effectively help patients lower their risk of life-threatening diseases.

Power research communities

Our secure digital platform enables researchers to construct and validate new Polygenic Risk Scores on multiple populations using the top algorithms in parallel to reveal the best Polygenic Risk Scores.

Funded by:

Allelica, Inc. - All rights reserved